AVEO Pharmaceuticals Inc (AVEO)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

30 WINTER STREET BOSTON, MA 02108

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cancer therapeutics. Tivozanib The company's primary product candidate, Tivozanib is an oral inhibitor of the vascular endothelial growth factor (VEGF) receptors 1, 2 and 3. The company initiated a phase 3 clinical trial of tivozanib in patients with advanced RCC in December 2009. The company is also conducting phase 1b clinical trials of tivozanib in various combinations and dosing regimens in advanced RCC and additional solid tumor indications, including breast cancer, colorectal cancer and lung cancer. In addition to tivozanib, the company has a pipeline of monoclonal antibodies derived from its Human Response Platform, a method of building preclinical models of human cancer, which are intended to represent cancer biology in patients. The company has a license agreement with Kyowa Hakko Kirin under which it obtained a license to research, develop, manufacture and commercialize tivozanib, pharmaceutical compositions thereof and associated biomarkers. Its license covers all territories in the world, except for Asia. Kyowa Hakko Kirin has retained rights to tivozanib in Asia, including the People's Republic of China, India, and Japan. AV-299 The company's product candidate derived from its Human Response Platform, AV-299, is expected to enter phase 2 clinical trials for multiple cancer types, including a phase 2 clinical trial for non-small cell lung cancer. In 2008, the company commenced a phase 1 clinical trial of AV-299 in patients with various solid tumors to establish the safety, tolerability, pharmacokinetics, maximum tolerated dose and the recommended phase 2 clinical trial dose of AV-299 as monotherapy. The company is also conducting a phase 1 clinical trial in cancer patients with liver metastases to evaluate the activity of AV-299 in HGF pathway activation in metatastic tumors. Additionally, a phase 1 clinical trial is also being initiated to evaluate the ability of AV-299 to cross the blood brain barrier in patients suffering from primary brain cancer. The company has an agreement with Merck, through its subsidiary Schering Corporation, acting through its Schering-Plough Research Institute division, under which it granted Merck worldwide, rights to develop and commercialize all of its monoclonal antibody antagonists of hepatocyte growth factor, or HGF, including AV-299, for therapeutic and prophylactic use in humans and for veterinary use. It also granted Merck a worldwide license to related biomarkers for diagnostic use. AV-203: Anti-ErbB3 Antibody Program The company's AV-203 program is focused on identifying inhibitors of ErbB3 and is in preclinical development. The company granted Biogen Idec an option to co-develop and commercialize its ErbB3-targeted antibodies for the potential treatment and diagnosis of cancer and other diseases outside of the United States, Canada, and Mexico. In March 2009, the company entered into an option and license agreement with Biogen Idec International GmbH, a subsidiary of Biogen Idec Inc., which are collectively referred to herein as Biogen Idec, regarding the development and commercialization of its discovery-stage ErbB3-targeted antibodies for the potential treatment and diagnosis of cancer and other diseases outside of the United States, Canada, and Mexico. Other Antibody Pipeline Programs In addition to the HGF/c-Met pathway and ErbB3, the company utilized its Human Response Platform to identify various other targets that appear to be potent drivers of tumor growth. Agreements The company has collaboration with Merck, a license and research collaboration agreement relating to the use of its Human Response Platform. Under the terms of the agreement, Merck obtained rights to all inventions and discoveries developed in the conduct of the collaborative research program that relate to Merck's proprietary cancer compounds, including gene expression patterns that correlate with a response to Merck's compounds. The company has a collaboration and license agreement with OSI Pharmaceuticals, Inc., or OSI, which provides for the use of its proprietary in vivo models by its scientists at its facilities, use of its bioinformatics tools and other target validation and biomarker research to develop and OSI's small molecule drug discovery and translational research related to cancer and other diseases. Competition Tivozanib: The company competes with Roche Laboratories, Inc. (Roche), Bayer HealthCare AG (Bayer), Onyx Pharmaceuticals, Inc., Pfizer Inc. (Pfizer), GlaxoSmithKline plc (GSK), Novartis Pharmaceuticals Corporation, Amgen Inc., Takeda Pharmaceutical Company Limited, AstraZeneca plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Exelixis Inc., ImClone LLC, Onco Therapy Science Inc., Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis US LLC. AV-299: The company competes with Amgen, Takeda, Roche, ArQule, Inc./Daiichi Sankyo, Inc., MethylGene, Inc., Exelixis, GSK, Pfizer, Exelixis, and BMS. AV-203 Program: The company competes with Merrimack Pharmaceuticals, Inc., Sanofi-Aventis, Daiichi Sankyo, Amgen, PharmaMar, and Merrimack. History The company was founded in 2001.

Data as of 2021-05-08 10:59:28 -0400
Market Cap220.94 Million Shares Outstanding34.361 Million Avg 30-day Volume776.799 Thousand
P/E Ratio-6.20896 Dividend Yield EPS-1.66
Price/Sales36.71 Debt to Equity1.9 EBITDA-38.856 Million
Price to Book Value6.26 Forward PE-3.16 Enterprise Value172.951 Million
Total Cash61.761 Million Current Debt16.945 Million Gross Profit6.019 Million
BETA0.8454 52-week High/Low18.24 / 4.07 Next Earnings Date Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from AVEO instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 68 65 4.62% 21 (1.26%) 18 (1.12%) 16.67%
13F shares: 10.48 Million 9.727 Million 7.73% 2.444 Million 1.88 Million 30.04%
% Ownership 36.376 33.7645 7.73% 8.4842 6.5243 30.04%
New Positions: 14 13 7.69% 7 6 16.67%
Increased Positions 25 22 13.64% 8 3 166.67%
Closed Positions 11 15 -26.67% 4 10 -60.0%
Reduced Positions 9 15 -40.0% 3 7 -57.14%
Total Calls 1.005 Million 1.089 Million -7.63% 70.7 Thousand 82.9 Thousand -14.72%
Total Puts 294.896 Thousand 288.875 Thousand 2.08% 40.731 Thousand 34.601 Thousand 17.72%
PUT/CALL Ratio 0.29 0.27 7.41% 0.58 0.42 38.1%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding AVEO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AVEO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

CULLEN KEVIN JOSEPH

  • Director
0 2021-04-15 2

EPPERLY CORINNE

  • Director
25,000 2021-04-13 3

FERRARESSO MICHAEL CHIEF COMMERCIAL OFFICER

  • Officer
3,284 2021-03-10 1

BAILEY MICHAEL P PRESIDENT & CEO

  • Officer
  • Director
275,000 2021-02-05 1

NEEDLE MICHAEL N CHIEF MEDICAL OFFICER

  • Officer
100,000 2021-02-05 1

LUCERA ERICK CHIEF FINANCIAL OFFICER

  • Officer
100,000 2021-02-05 1

GROWTH EQUITY OPPORTUNITIES FUND IV, LLC

NEW ENTERPRISE ASSOCIATES 15, L.P.

NEA PARTNERS 15, L.P.

NEA 15 GP, LLC

  • 10% Owner
3,952,958 2020-06-19 1

FLORENCE ANTHONY A. JR.

  • 10% Owner
3,952,958 2020-06-19 1

BASKETT FOREST

  • 10% Owner
3,952,958 2020-06-19 1

MAKOWER JOSHUA

  • 10% Owner
3,952,958 2020-06-19 1

SANDELL SCOTT D

  • 10% Owner
3,952,958 2020-06-19 1

SONSINI PETER W.

  • 10% Owner
3,952,958 2020-06-19 1

MAKHZOUMI MOHAMAD

  • 10% Owner
3,952,958 2020-06-19 1

YOUNG ROBERT C

  • Director
0 2020-06-10 1

BATE KENNETH

  • Director
0 2020-06-10 1

EVNIN ANTHONY B

  • Director
0 2020-06-10 1

MAYES, GREGORY T.

  • Director
0 2020-06-10 1

SPRING SCARLETT

  • Director
0 2020-06-10 1

RUBIN KARUNA SVP AND GENERAL COUNSEL

  • Officer
0 2020-02-05 0

BARRIS PETER J

  • 10% Owner
25,243,865 2019-04-08 0

MOTT DAVID M

  • 10% Owner
25,243,865 2019-04-08 0

DALLAS MATTHEW D CHIEF FINANCIAL OFFICER

  • Officer
0 2019-02-06 0

MEHTA NIKHIL SEE REMARKS

  • Officer
0 2019-02-06 0

MAKOWER JOSHUA

MAKOWER JOSHUA

  • 10% Owner
62,388,114 2018-12-20 1

VISWANATHAN RAVI

  • 10% Owner
18,698,038 2018-08-21 0

SAKODA JON

  • 10% Owner
17,783,722 2018-06-27 0

PUTTAGUNTA CHETAN

  • 10% Owner
17,783,722 2018-06-27 0

JOHNSON JOHN

  • Director
0 2018-02-01 0

EHRLICH KEITH S CHIEF FINANCIAL OFFICER

  • Officer
121,813 2017-03-28 0

TERMEER HENRI A

  • Director
0 2016-05-26 0

KOLLURI KRISHNA KITTU

  • 10% Owner
10,362,694 2016-05-13 0

WELLER HARRY R

  • 10% Owner
10,362,694 2016-05-13 0

HA NGOC TUAN

  • Director
0 2015-05-28 0

KUCHERLAPATI RAJU S

  • Director
0 2015-05-28 0

GYURIS JENO SVP, CHIEF SCIENTIFIC OFFICER

  • Officer
76,131 2015-01-06 0

VITTIGLIO JOSEPH SVP, GENERAL COUNSEL

  • Officer
16,437 2015-01-06 0

SLICHENMYER WILLIAM CHIEF MEDICAL OFFICER

  • Officer
35,113 2014-01-29 0

JOHNSTON DAVID BRANNON CHIEF FINANCIAL OFFICER

  • Officer
46,837 2013-10-02 0

WEG KENNETH E

  • Director
47,757 2013-07-01 0

EZICKSON ELAN CHIEF OPERATING OFFICER

  • Officer
61,843 2013-01-24 0

JONES MARY ELLEN SVP, HUMAN RESOURCES

  • Officer
36,000 2013-01-24 0

EPSTEIN ROBERT S

  • Director
0 2012-12-18 0

ROBINSON MURRAY O. SVP, TRANSLATIONAL MEDICINE

  • Officer
141,745 2012-09-28 0

DEPINHO RONALD A

  • Director
0 2012-05-30 0

GALAKATOS NICHOLAS

  • Director
0 2011-06-01 0

COLE DOUGLAS G.

  • Director
1,444,795 2011-05-12 0

HIRSCH RUSSELL C

  • Director
1,289,483 2010-12-02 0

MPM BIOVENTURES II QP LP

MPM BIOVENTURES II LP

MPM ASSET MANAGEMENT II LLC

MPM ASSET MANAGEMENT INVESTORS 2002 BVII LLC

MPM BIOVENTURES GMBH & CO PARALLEL BETEILIGUNGS KG

MPM ASSET MANAGEMENT II LP

EVNIN LUKE

GADICKE ANSBERT

STEINMETZ MICHAEL

WHEELER KURT

  • FORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDER
No longer subject to file 2010-03-17 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

CULLEN KEVIN JOSEPH - Director

2021-04-27 07:48:24 -0400 2021-04-15 A 25,000 a 25,000 direct

EPPERLY CORINNE - Director

2021-04-14 18:21:55 -0400 2021-04-13 A 15,000 a 15,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
AVEO PHARMACEUTICALS INC AVEO 2021-05-10 22:15:04 UTC -1.2584 1.3084 900000
AVEO PHARMACEUTICALS INC AVEO 2021-05-10 21:45:02 UTC -1.2584 1.3084 900000
AVEO PHARMACEUTICALS INC AVEO 2021-05-10 21:15:02 UTC -1.2584 1.3084 900000
AVEO PHARMACEUTICALS INC AVEO 2021-05-10 20:45:03 UTC -1.2269 1.2769 900000
AVEO PHARMACEUTICALS INC AVEO 2021-05-10 20:15:03 UTC -1.2269 1.2769 900000
AVEO PHARMACEUTICALS INC AVEO 2021-05-10 19:45:03 UTC -1.2269 1.2769 900000
AVEO PHARMACEUTICALS INC AVEO 2021-05-10 19:15:03 UTC -1.2269 1.2769 900000
AVEO PHARMACEUTICALS INC AVEO 2021-05-10 18:45:03 UTC -1.2037 1.2537 900000
AVEO PHARMACEUTICALS INC AVEO 2021-05-10 18:15:03 UTC -1.2037 1.2537 900000
AVEO PHARMACEUTICALS INC AVEO 2021-05-10 17:45:02 UTC -1.2037 1.2537 900000
AVEO PHARMACEUTICALS INC AVEO 2021-05-10 17:15:03 UTC -1.2037 1.2537 900000
AVEO PHARMACEUTICALS INC AVEO 2021-05-10 16:45:03 UTC -1.2037 1.2537 900000
AVEO PHARMACEUTICALS INC AVEO 2021-05-10 16:15:03 UTC -1.2037 1.2537 900000
AVEO PHARMACEUTICALS INC AVEO 2021-05-10 15:45:03 UTC -1.2037 1.2537 650000
AVEO PHARMACEUTICALS INC AVEO 2021-05-10 15:15:03 UTC -1.2037 1.2537 650000
AVEO PHARMACEUTICALS INC AVEO 2021-05-10 14:45:04 UTC -0.8794 0.9294 650000
AVEO PHARMACEUTICALS INC AVEO 2021-05-10 14:15:04 UTC -0.8794 0.9294 650000
AVEO PHARMACEUTICALS INC AVEO 2021-05-10 13:45:04 UTC -0.8794 0.9294 650000
AVEO PHARMACEUTICALS INC AVEO 2021-05-10 13:15:03 UTC -0.8794 0.9294 600000
AVEO PHARMACEUTICALS INC AVEO 2021-05-10 12:45:02 UTC -0.8794 0.9294 550000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments